Lista de obras - Vincenzo Di Nunno - Dominio Público Uruguay

A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor

artículo científico publicado en 2018

Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials

artículo científico publicado en 2019

Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies

artículo científico publicado en 2018

Adjuvant therapy in renal cell carcinoma.

artículo científico publicado en 2017

Adjuvant therapy in renal cell carcinoma—is pharmacogenomics assessment another element to select our patients?

artículo científico publicado en 2019

An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer

artículo científico publicado en 2019

Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma

scientific article published on 01 July 2019

Atezolizumab for platinum-treated metastatic urothelial carcinoma

artículo científico publicado en 2017

Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer

artículo científico publicado en 2018

Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients

scientific article published on 31 March 2019

CheckMate 214 patient-reported outcomes: listening to our patients

scientific article published on 15 January 2019

Circulating tumor cells in genitourinary tumors.

artículo científico publicado en 2017

Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma

artículo científico publicado en 2018

Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?

artículo científico publicado en 2018

Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy

scientific article published on 21 May 2020

Future perspectives for personalized immunotherapy in renal cell carcinoma.

artículo científico

Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue

scientific article published on 16 January 2019

Immune checkpoint inhibitors for metastatic bladder cancer

artículo científico publicado en 2018

Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis

artículo científico publicado en 2018

Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice

artículo científico publicado en 2019

Immunotherapy in renal cell carcinoma: latest evidence and clinical implications.

artículo científico publicado en 2018

Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer?

scientific article published on 01 September 2018

Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers

scientific article published on 22 August 2019

Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer

artículo científico publicado en 2019

Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies

scientific article published on 11 September 2019

New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes

scientific article published on 08 July 2019

Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution

scientific article published on 01 June 2019

Optimizing renal function and outcome of patients with cT2 renal cell carcinoma

scientific article published on 01 March 2019

Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity.

artículo científico

Prostate cancer heterogeneity: Discovering novel molecular targets for therapy

artículo científico publicado en 2017

Prostate cancer pathology: What has changed in the last 5 years

scientific article published on 23 September 2019

Re: Gladell P. Paner, Walter M. Stadler, Donna E. Hansel, Rodolfo Montironi, Daniel W. Lin, Mahul B. Amin. Updates in the Eighth Edition of the Tumor-node-metastasis Staging Classification for Urologic Cancers. Eur Urol 2018;73:560-9: Tumour, Node, a

scientific article published on 13 July 2018

Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462-8

scientific article published on 12 April 2018

Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. Lancet Oncol 201

artículo científico publicado en 2018

Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2

artículo científico publicado en 2017

Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer

Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor

artículo científico publicado en 2019

Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy

artículo científico publicado en 2018

Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors.

artículo científico publicado en 2015

Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies

artículo científico publicado en 2019

The Human Microbiota and Prostate Cancer: Friend or Foe?

artículo científico publicado en 2019

Tivozanib for the treatment of renal cell carcinoma.

artículo científico publicado en 2018

Toward a genome-based treatment landscape for renal cell carcinoma

scientific article published on 02 August 2019

Lista de obras de Vincenzo Di Nunno

A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor

Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials

Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies

Adjuvant therapy in renal cell carcinoma.

Adjuvant therapy in renal cell carcinoma—is pharmacogenomics assessment another element to select our patients?

An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer

Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma

Atezolizumab for platinum-treated metastatic urothelial carcinoma

Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer

Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients

CheckMate 214 patient-reported outcomes: listening to our patients

Circulating tumor cells in genitourinary tumors.

Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma

Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?

Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy

Future perspectives for personalized immunotherapy in renal cell carcinoma.

Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue

Immune checkpoint inhibitors for metastatic bladder cancer

Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis

Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice

Immunotherapy in renal cell carcinoma: latest evidence and clinical implications.

Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer?

Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers

Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer

Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies

New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes

Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution

Optimizing renal function and outcome of patients with cT2 renal cell carcinoma

Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity.

Prostate cancer heterogeneity: Discovering novel molecular targets for therapy

Prostate cancer pathology: What has changed in the last 5 years

Re: Gladell P. Paner, Walter M. Stadler, Donna E. Hansel, Rodolfo Montironi, Daniel W. Lin, Mahul B. Amin. Updates in the Eighth Edition of the Tumor-node-metastasis Staging Classification for Urologic Cancers. Eur Urol 2018;73:560-9: Tumour, Node, a

Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462-8

Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. Lancet Oncol 201

Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2

Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer

Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor

Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy

Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors.

Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies

The Human Microbiota and Prostate Cancer: Friend or Foe?

Tivozanib for the treatment of renal cell carcinoma.

Toward a genome-based treatment landscape for renal cell carcinoma